Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The University of Kansas Announces Grant Funding for Knee Imaging Biomarkers Acquired from Weight Bearing CT

The University of Kansas Medical Center Research Institute Department of Rehabilitation Medicine has received a grant from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), to fund three years of research on the usefulness of bilateral weight bearing CT…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

The University of Kansas Medical Center Research Institute Department of Rehabilitation Medicine has received a grant from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), to fund three years of research on the usefulness of bilateral weight bearing CT imaging and the critical need for more sensitive and affordable imaging biomarkers.

Osteoarthritis (OA) is the most prevalent form of arthritis, and the knee is the most commonly affected weight-bearing joint. The high cost of clinical trials creates a barrier for effective treatment development. Therefore, introduction of more specific and sensitive biomarkers could help to advance therapeutic development by reducing the time and sample sizes required for clinical trials.

Proposed Outcomes

There is an urgent need for imaging biomarkers that allow for identification of the best time in which patients will respond to treatment, and a means to analyze the efficiency of interventions. Early studies demonstrated the diagnostic value of bilateral weight-bearing CT in identifying knee OA symptoms accurately, as well as the feasibility to detect meniscal tears not detected by non-weight bearing MRI.

The grant from NIAMS will fund a study to validate the proposed imaging biomarkers and begin the qualification process for more responsive OA imaging biomarkers acquired using low-dose, bilateral standing CT imaging. Substantial advantages are offered over traditional radiographic biomarkers, including increased responsiveness to temporal changes in the joints, and a better reflection of the symptoms and severity of the disease. Additionally, this research will determine the prognostic validity of standing CT findings for detecting progression and worsening pain in people who currently suffer from or are at risk for knee OA.

Long-Term Impact

With the support of NIAMS, this research holds promise to detect joint damage earlier, and accelerate the pace of scientific discovery and clinical trials. The continuing impact will be evident through a shift in knee joint imaging with an improved biomarkers for monitoring knee OA disease features. If the additional meniscal extrusions detected on bilateral standing CT are clinically relevant, then standing CT could improve identification of the most appropriate patients for clinical trials – those at risk of rapid OA progression. Successful completion will provide improved biomarkers that will help those who suffer from knee OA through making clinical trials more affordable and accelerating therapeutic improvement.

For more information on visualizing cartilage and menisci in the knee using standing CT arthrogram versus MRI, click here.

Read more at curvebeam.com

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tempus AI's $1.7B Personalis deal leads a surge in health-tech M&A that is already reshaping vendor choices for health system operators

Tempus AI's $1.7B Personalis deal leads a surge in health-tech M&A that is already reshaping vendor choices for health system operators

Digital health mergers and acquisitions (M&A) along with venture capital (VC) activities are rapidly increasing. Tempus AI's $1.7 billion acquisition of Personalis is part of a larger trend that is influencing health system operators’ selection of vendors. With $7.4 billion in funding during the first half of 2026, the health-tech industry is undergoing significant transformation.

  • 01Tempus AI acquired Personalis for $1.7 billion.
  • 02Health-tech received $7.4 billion in funding in the first half of 2026.
  • 03M&A activities are influencing vendor choices for health system operators.

Jul 30, 2026

Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

In the first half of 2026, digital health AI investments reached $7.4 billion as organizations like CMS, hospitals, and startups increased their adoption of AI. Significant moves include the establishment of a new CMS technology office and a $1.7 billion acquisition in cancer technology. These developments mark an enterprise-level commitment to advancing AI in healthcare.

  • 01Digital health AI investments reached $7.4 billion in H1 2026.
  • 02The CMS established a new technology office to advance healthcare AI.
  • 03A major acquisition in cancer technology totaled $1.7 billion.

Jul 30, 2026

Sensor networks and AI push structural health monitoring toward a $8.6 billion market by 2035

Sensor networks and AI push structural health monitoring toward a $8.6 billion market by 2035

The global structural health monitoring (SHM) market is projected to surpass $8.6 billion by 2035. This growth is fueled by the integration of AI analytics, wireless sensor technologies, and the necessity to address aging infrastructure. The expansion reflects a widespread adoption of these technologies in various sectors.

  • 01The SHM market is expected to exceed $8.6 billion by 2035.
  • 02Advancements in AI-powered analytics and wireless sensors are key drivers of market growth.
  • 03Aging infrastructure is creating a demand for enhanced structural health monitoring solutions.

Jul 24, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512